Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Twist Bioscience Corp Director's Dealing 2018

Oct 30, 2018

31873_dirs_2018-10-30_0498bb95-a7d9-4458-a4e0-fb6a203f9da7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Twist Bioscience Corp (TWST)
CIK: 0001581280
Period of Report: 2018-10-30

Reporting Person: CRANDELL KEITH (Director, 10% Owner)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Series A Preferred Stock $ Common Stock (1182645) Indirect
Series B Preferred Stock $ Common Stock (718275) Indirect
Series C Preferred Stock $ Common Stock (266776) Indirect
Series D Preferred Stock $ Common Stock (224726) Indirect
Series D Preferred Stock $ Common Stock (894146) Indirect

Footnotes

F1: The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and automatically convert into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering.

F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F3: Keith Crandell is a managing director of ARCH VII LLC and AVP GPLLC, and may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Mr. Crandell disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F4: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.